Baillie Gifford & CO Ionis Pharmaceuticals Inc Call Options Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IONS
# of Institutions
402Shares Held
136MCall Options Held
862KPut Options Held
582K-
Vanguard Group Inc Valley Forge, PA15.1MShares$533 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.2MShares$502 Million0.34% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$365 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.74MShares$309 Million0.06% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.87MShares$279 Million5.32% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $5.02B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...